Skip to main content
. 2012 Jul;342(1):33–40. doi: 10.1124/jpet.112.192195

Fig. 1.

Fig. 1.

Intracellular accumulation of vemurafenib in MDCKII cells. A, accumulation of vemurafenib is significantly lower in Bcrp-transfected lines compared with its WT control. The difference in accumulation was abolished when a specific Bcrp inhibitor, Ko143, was used. B, the accumulation of vemurafenib is ∼20% less in MDR1-transfected cells than the WT controls, and the difference was abolished when the MDR1-specific inhibitor LY335979 was used. Data represent mean ± S.D. (n = 3–6 for all data sets). **, p < 0.01; ***, p < 0.0001.